CNIO - Spanish National Cancer Research Centre
Nuria Ajenjo has extensive experience in cancer research and pharmacology, currently serving as part of the CNIO-Spanish National Biobank Network and the Experimental Therapeutics Program at CNIO since May 2009, focusing on anti-cancer drug discovery and molecular pharmacology. Previously, Nuria worked as a researcher at Projech, where efforts centered on anti-obesity drug screening and adipocyte regulation. Prior roles at CNIO and EMBL involved research on cell cycle regulation and signaling pathways related to cancer. Early career experience includes postdoctoral fellowships at the University of Cantabria, where research revolved around cartilage viability and interactions between proto-oncogen c-Myc and tumor suppressor p53, as well as studies on Ras signaling at Centro de Investigación del Cancer. Nuria holds a PhD in Biological Sciences from the University of Cantabria and a Bachelor's degree in Biochemistry from the University of Oviedo.
This person is not in any teams
CNIO - Spanish National Cancer Research Centre
The Spanish National Cancer Research Centre is a public institution of excellence committed to research, diagnosis and treatment for cancer. The CNIO currently houses 22 Research Groups, organised in 7 Scientific Programmes, plus 5 Clinical Research Unit(s) that work closely with several hospitals. These scientific groups are supported by 19 Core Units that provide state-of-the-art facilities and technical expertise. The CNIO also has an Experimental Therapeutics Programme leader in academic drug discovery. Since 2011, CNIO is recognised a one of the ‘Severo Ochoa’ Centres of Excellence by the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación -------------------------------- El Centro Nacional de Investigaciones Oncológicas (CNIO) es una institución pública española dedicada a la investigación, diagnóstico y tratamiento del cáncer. El CNIO cubre todo el recorrido de la I+D+i, desde la investigación básica hasta la clínica. Actualmente el CNIO tiene 22 Grupos de Investigación, organizados en 7 Programas Científicos, más 5 Unidades de Investigación Clínica que trabajan estrechamente con varios hospitales. En el CNIO hay 19 Unidades de Apoyo a la Investigación dotadas de las más modernas instalaciones y conocimientos técnicos. El CNIO también tiene un Programa de Terapias Experimentales de referencia en el descubrimiento de nuevos fármacos. Desde el 2011, el CNIO es uno de los Centros de Excelencia Severo Ochoa acreditados por la Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación.